DOCSLIB.ORG

Featured Article Columbia Researchers United Against COVID-19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Featured Article Columbia Researchers United Against COVID-19 Summer/Fall COLUMBIA PATHOLOGY 2020 AND CELL BIOLOGY REPORT Featured Article Columbia Researchers United Against COVID-19 Lab Snapshot Effects of COVID-19 on Histology Lab COVID-19 Response Departmental collection of the clinical response to the pandemic in this issue 3 From the Chair 4 Honors and Awards 9 Faculty Promotions 10 Grants Awarded 13 In Memoriam 15 New Administrative Staff 16 New Faculty 7 17 Research 18 COVID-related Research 20 Feature Article: Columbia Researchers United Build a COVID-19 Patient Biobank 27 Lab Snapshot: Impact of COVID-19 on Histology 28 New Residents & Fellows Columbia Pathology and Cell Biology Report Chairman Kevin A. Roth, MD, PhD Donald W. King, M.D. and Mary Elizabeth King, M.D. Professor of Pathology and Cell Biology Chair, Department of Pathology and Cell Biology Pathologist-in-Chief, CUIMC Department Administrator/CFO Joann Li, PA, MPH Editor and Layout Designer 20 Milan Fredricks Copy Editor and Webmaster Ping Feng Contributing Writers Alvaro Cuesta-Dominguez, Phd Annette Wu, MD Address correspondence to: PCB Reports, Editor c/o Milan Fredricks Columbia University Department of Pathology and Cell Biology 630 W. 168th St., Box 23 New York, NY 10032 E-mail: [email protected] Website: pathology.columbia.edu on the cover: Illustration, men and women wearing masks 24 (Source: graphics4u on envato elements) FROM THE CHAIR A Changing Landscape ARS -CoV-2 had, and world to advance studies of continues to have, a the virus and to develop novel Grants Awarded Sdevastating effect on our SARS-CoV-2 assays and therapies community. At its peak in mid- (https://www.pathology.columbia. In Memoriam April, we had over 600 SARS- edu/departmental-covid-19- CoV-2 patients admitted to NYP- article-collection). CUIMC with over 200 patients on ventilators. To date, SARS-CoV-2 Many of these efforts are has resulted in over 3000 patient highlighted in this newsletter Research admissions and more than 500 and detailed further on our deaths at NYP-CUIMC. Tragically, departmental website (https:// Kevin A. Roth, M.D., Ph.D., Chair the pandemic outbreak of SARS- www.pathology.columbia.edu/). [email protected] CoV-2 has disproportionally I encourage everyone in the affected vulnerable populations department, particularly those including elderly and patients returning to onsite work duties, with co-morbidities such as to continue to be vigilant and to cancer and other immune follow all Columbia University and deficiencies. NYP-CUIMC guidelines for keeping yourself and your colleagues safe. Recently released Federal data indicate that Blacks and Hispanics Finally, I want to thank each of are three-times as likely as whites you, whether you are working to be infected and twice as likely from home or at CUIMC, for to die from Covid-19. Thankfully, everything you have contributed the number of new cases has to our clinical, research and decreased significantly over educational missions during this the last few months and some pandemic. I am hopeful that a aspects of pre-Covid-19 life have second wave of cases doesn’t begun to re-emerge. Although occur in the coming months but these are good indictors, we I am confident that if it does, we must be prepared for a rise will once again face the challenge in cases over the upcoming with professionalism and months as social distancing and compassion. ◆ other precautions become less rigorously followed. Best wishes, The Department of Pathology and Cell Biology has been integral to the clinical response to the pandemic and has partnered with numerous colleagues and collaborators throughout the 4 PCB REPORTS Honors and Awards Jay Lefkowitch, MD Brie Stotler, MD Dr. Jay Lefkowitch and Dr. Brie Stotler Accepted into ACE Congratulations to Jay Lefkowitch, MD, professor of ACE also includes the following faculty members from pathology and cell biology at CUMC, and Brie Stotler, the Department of Pathology and Cell Biology, inducted MD, assistant professor of pathology and cell biology since the launch of ACE: at CUMC, who have been recently accepted into the 2020 class of the Academy of Clinical Excellence Govind Bhagat, MBBS - Professor of Pathology and Cell (ACE). Biology at CUMC Vivette D. D’Agati, MD - Professor of Pathology and Cell The Columbia University Vagelos College of Physicians Biology at CUMC and Surgeons Academy of Clinical Excellence (ACE) Hanina Hibshoosh, MD - Professor of Pathology and was established in 2016 to define, recognize, and Cell Biology at CUMC perpetuate excellence in clinical care by faculty, Charles C. Marboe, MD - Professor of Pathology and trainees, and students. It honors the clinical faculty Cell Biology at CUMC who contribute to the Vagelos College of Physicians Glen S. Markowitz, MD - Professor of Pathology and and Surgeons through patient care marked by Cell Biology at CUMC evidence-based clinical science coupled with deeply Kathleen M. O’Toole, MD - Professor of Pathology and compassionate humanism. Each member of ACE Cell Biology at CUMC exhibits excellence in the following characteristics: Anjali Saqi, MD, MBA - Professor of Pathology and Cell reputation, communication and interpersonal Biology at CUMC skills, professionalism and humanism, diagnostic Joseph Schwartz, MD, MPH - Professor of Pathology acumen, skillful negotiation of the health care and Cell Biology at CUMC system, knowledge, scholarly approach to clinical David N. Silvers, MD - Professor of Dermatology and care, commitment to mentoring trainees and junior Pathology and Cell Biology at CUMC colleagues, and passion for clinical medicine. Steven L. Spitalnik, MD - Professor of Pathology and Cell Biology “Well deserved honor for both of you and the Matthias J. Szabolcs, MD - Professor of Pathology and department”, said Dr. Kevin Roth, the department Cell Biology at CUMC chair, congratulating Dr. Lefkowitch and Dr. Stotler for achieving this remarkable honor. SUMMER/FALL 2020 5 Honors and Awards Dr. Eldad Hod Elected to the NBF Hall of Fame The National Blood Foundation has Currently, Dr. Hod is conducting research to determine just announced Eldad Hod, MD as whether plasma from those who have recovered from one of its two newest members of COVID-19 could be used to treat those who are infected. the NBF Hall of Fame. We warmly NBF introduced its Hall of Fame in 2007 recognizing a congratulate Dr. Hod for achieving prestigious and select group of NBF grant recipients who this remarkable recognition! leveraged their early-career grant funding into successful careers in transfusion medicine, cellular therapies, or Dr. Eldad Hod is an associate professor of pathology patient blood management and who demonstrated and cell biology, as well as a researcher and expert in exemplary leadership within the field. This important transfusion medicine. His research investigates important recognition was reinstated annually in 2015 inducting one problems related to red blood cell transfusion and iron to three new members each year. biology. He has received several awards including the Jean Julliard Prize and the Jack Latham Memorial Award for The NBF Research and Recognition Awards are scheduled Innovative Research from the National Blood Foundation in to be presented at the AABB Annual Meeting in October 2014 and was named an NBF scholar in the same year. 2020 in Baltimore, MD. OTHER HONORS AND AWARDS Dritan Agalliu, PhD The Harold and Golden Lamport Award for Excellence in Basic Science Research Dr. Minah Kim Wins VELOCITY Osama Al Dalahmah, MD, PhD Translational Therapeutics Accelerator Pilot Award Cancer Research Award Francesca Bartolini, PhD Herbert Irving Comprehensive Cancer Fulbright specialist in 2019 Center Leadership just announced that Mina Kim, PhD, assistant professor of Ibrahim Batal, MD pathology and cell biology at Columbia 2020-2021 Mendez National Institute of Transplantation University Irving Medical Center, has Foundation Research Grant been selected as one of this year’s Velocity Fellows for her research Eunhee Choi, PhD project entitled “Targeting Vascular Winner, Alice Bohmfalk Charitable Trust Award Abnormalities to Overcome Immune Checkpoint Inhibitor Resistance in Catherine Clelland, PhD Metastatic Melanoma”. Winner, Translational Therapeutics Accelerator Pilot Award Dr. Kim is studying mechanisms by Erin Heinzen Cox, PharmD, PhD which vascular abnormalities lead Named 2019 Irving Scholars to therapeutic resistance to immune checkpoint inhibitor in patients with Serge Cremers, PhD, PharmD melanoma and drug combinations Named Editor-in-Chief of the British Journal of Clinical that could reverse resistance. This Pharmacology (BJCP) information will also help find potential Piero Dalerba, MD vascular biomarker to predict patient 2019 Velocity Fellow responses to therapy. Vivette D’Agati, MD To learn more about the award, read Castle Connolly Top Doctors for 2020 the full announcement at HICCC News. 6 PCB REPORTS Honors and Awards Dr. Stuart Weisberg Named 2020 Louis V. Gerstner Jr. Scholar Stuart Weisberg, MD, PhD, assistant professor of high-resolution immunophenotypic, transcriptomic pathology and cell biology, has been appointed to and functional analysis. In parallel, he performs a three year term as a Louis V. Gerstner Jr. scholar multispectral staining of pancreas tissue sections to effective July 1, 2020 through June 30, 2023. examine the spatial interrelationships between these pancreatic immune cells and their position within the Each year since 2008, the Louis V. Gerstner Jr. tissue microenvironment. His studies now are focusing Scholars Program has supported tenure-track on mechanisms of pancreatic inflammation and physicians who conduct research that has the promise how obesity and type 2 diabetes alter the pancreatic to bring new treatments to patients. The fund provides immune landscape to increase risk for pancreatitis and a stipend of $75,000 per year, for up to three years, to pancreatic cancer. support the awardees’ research projects. Scholars are nominated by a committee of distinguished research As an MD/PhD student, Stuart’s doctoral work in faculty and selected by the VP&S dean. the lab of Drs. Anthony Ferrante and Rudolph Leibel revealed that obesity is associated with accumulation Dr.
Load more

Recommended publications
  • Skinny and 119 Pounds, but with the Health Hallmarks of Obesity - the New York Times 7/22/16, 2:42 PM
    Skinny and 119 Pounds, but With the Health Hallmarks of Obesity - The New York Times 7/22/16, 2:42 PM http://nyti.ms/2aeHHnQ Skinny and 119 Pounds, but With the Health Hallmarks of Obesity A small group of thin patients who develop disorders typically tied to obesity pose a medical mystery and a potential opportunity for scientists. By GINA KOLATA JULY 22, 2016 Claire Walker Johnson of Queens was a medical mystery. No matter how much she ate, she never gained weight. And yet Ms. Johnson, with a long narrow face, had the conditions many obese people develop — Type 2 diabetes, high blood pressure, high cholesterol and, most strikingly, a liver buried in fat. She and a very small group of very thin people like her have given scientists surprising clues to one of the most important questions about obesity: Why do fat people often develop serious and sometimes life-threatening medical conditions? The answer, it turns out, has little to do with the fat itself. It’s about each person’s ability to store it. With that understanding, scientists are now working on drug treatments to protect people from excess unstored fat and spare them from dire medical conditions. The need is clear. One in three Americans and one in four adults worldwide have at least three conditions associated with obesity such as diabetes, high cholesterol and high blood pressure — a combination of disorders that doubles their risk of heart attacks and strokes. In addition, 2 percent to 3 percent of adults http://www.nytimes.com/2016/07/26/health/skinny-fat.html?_r=0 Page 1 of 7 Skinny and 119 Pounds, but With the Health Hallmarks of Obesity - The New York Times 7/22/16, 2:42 PM in America, or at least five million people, have a grave accumulation of fat in their livers caused by obesity that can lead to liver failure.
    [Show full text]
  • Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston Editor, Transfusion Medicine Reviews Financial Disclosure
    The Present and Future of Medical Publication Sunny Dzik, MD Blood Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston Editor, Transfusion Medicine Reviews Financial Disclosure: Stipend from Elsevier Publishing for my role as Editor of Transfusion Medicine Reviews. I have no other conflicts of interest to declare. For 20 centuries In the 15th Century Moveable type ! 1450 Source: wikipedia Henry Oldenburg 1st Scientific Editor Introduced the idea of scientific peer review Source: insights.uksg.org For 20 centuries In the 15th Century Now 1450 The Internet is changing all aspects of medical publication 1. Business model for publishers. 2. Metrics to ”rank” scientific publication. 3. Opportunity for fraud, plagiarism & the ability to catch it. 4. Dimensions of information transfer. 5. Sheer volume of information and importance of quality. 1. Business Models for Medical Publication Individual subscription model becoming extinct. Publishers sell a ‘bundle’ of journal titles to libraries. Users access individual articles on line. Packaging articles in “volumes” with “page numbers” may seem increasingly out-of-date.* *DOI = digital object identifier How Medical Libraries Used to Store Articles Medical College Library in Tanzania kcmuco.ac.tz/home/ ‘Open Access’ publishing . Article is made freely available to all online immediately after acceptance. Author, Institution, or Grant Funds pay an ‘article publication fee’. Some journals publish exclusively open access (PLOS, Biomed Central). Most journals are mix of subscription and open access options. Open access can offset subscription costs. Devised at the University of Leiden Vox Sanguinis: Open access $3300 Free self-archive access after 12 months Transfusion: Open access $3900 Free self-archive access after 12 months Transfusion Medicine Reviews: Open access $2500 Free self-archive access after 12 months Globally: Funders Embrace Open Access (but usually do not pay for it) Image courtesy of Elsevier 2.
    [Show full text]
  • Wendy Chung: Genetic Sleuth Is Advocate for Families
    Spectrum | Autism Research News https://www.spectrumnews.org PROFILES Wendy Chung: Genetic sleuth is advocate for families BY DEBORAH RUDACILLE 21 JULY 2011 Triple threat: Colleagues say that Wendy Chung combines strengths in teaching, research and patient care with a finely tuned ethical sensibility. A few months ago, a young woman walked into Wendy Chung's office with a notebook and a flash drive. She said, "Here's my medical history, here's my genome, now you figure out what caused all this." This is exactly the kind of challenge that Chung relishes. A skilled genetic detective, she is adept at tracing an individual's symptoms to a particular genetic anomaly, teasing out its molecular ramifications and identifying the associated syndrome. According to those who know her well, that analytical bent is accompanied by a rare sensitivity. "I've known a lot of brilliant doctors and though she's at the top of the brilliance list, she also has a humanistic philosophy that animates everything she does," says Hamilton Cain, the father of one of Chung's patients. "She's not only thinking on all cylinders, but also feeling on all cylinders. She really connects with patients and their stories and their lives." Chung, who began her research career studying diabetes and obesity, is director of the clinical 1 / 4 Spectrum | Autism Research News https://www.spectrumnews.org genetics program at Columbia University Medical Center in New York as well as the university's fellowship program in clinical and molecular genetics. Two years ago, she moved into the autism field, accepting an invitation to serve as the principal investigator of the Simons Variation in Individuals Project (VIP), launched by the Simons Foundation, SFARI.org's parent organization.
    [Show full text]
  • Storm Over Gender Gap Moves Into a Gray Area
    وزارة اﻟﺗرﺑﯾﺔ واﻟﺗﻌﻠﯾم اﻟﻌﺎﻟﻲ اﻣﺗﺣﺎﻧﺎت ﺷﮭﺎدة اﻟﺛﺎﻧوﯾﺔ اﻟﻌﺎﻣﺔ دورة ﺳﻨﺔ ۲۰۰٥ اﻟﻌﺎدﯾﺔ اﻟﻣدﯾرﯾﺔ اﻟﻌﺎﻣﺔ ﻟﻠﺗرﺑﯾﺔ ﻓﺮﻋﺎ اﻟﻌﻠﻮم اﻟﻌﺎﻣﺔ وﻋﻠﻮم اﻟﺤﯿﺎة داﺋرة اﻻﻣﺗﺣﺎﻧﺎت ﻣﺳﺎﺑﻘﺔ ﻓﻲ: اﻟﻠﻐﺔ اﻻﻧﻛﻠﯾزﯾﺔ اﻻﺳم: اﻟﻣدة: ﺳﺎﻋﺗﺎن وﻧﺻف اﻟرﻗم: Part One: Reading (Score: 11/20) The writer in this article highlights the essential role of the hormone leptin in controlling obesity. Read it carefully, then answer the questions that follow. Obesity Control 1 New studies on mice suggest that the hormone leptin can fundamentally change the brain’s circuitry in areas that control appetite. Leptin acts during a critical period early in life, possibly influencing how much animals eat as adults. And later in life, responding to how much fat is on an animal’s body, it can again alter brain circuitry that controls how much is eaten. Researchers say the findings are a surprise and help explain why weight control is so hard for some people. 2 Scientists knew that leptin is released by fat cells and that it tells the brain how much fat is on the body. They knew that animals lacking leptin become incredibly obese and that a few humans who, because of genetic mutations do not make the hormone, are also immensely fat. 3 Leptin injections immediately made animals and the handful of patients with leptin deficiencies lose their appetites. Their weight returned to normal. 4 But it was thought that leptin acted like most other hormones by attaching itself to brain cells and directly altering their activities. 5 Some investigators did not expect that leptin could actually change connections in the brain, strengthening circuits that inhibit eating and weakening those that spur appetite.
    [Show full text]
  • Annual Report 2020 2021 Table of Contents
    ANNUAL REPORT 2020 2021 TABLE OF CONTENTS • Mission, vision and goals 3 • Platelet Immunobiology Working Party 26 • Foreword from the President 4 • Quality Management Working Party 27 • Foreword from the Secretary General 6 • Rare Donor Working Party 29 • Board of Directors 7 • Red Cell Immunogenetics and Blood Group Terminology 30 • Membership 2020-2021 8 Working Party • Report from the Young Professionals Council 9 • Transfusion Transmitted Diseases Working Party 32 • Financial Summary 10 • Reports from ISBT Standing Committees 35 • Congresses 11 • ISBT Standing Committee of the ISBT Academy 36 • Reports from ISBT Working Parties 12 • ISBT Standing Committee on Ethics 39 • Blood Supply Management Working Party 13 • ISBT Standing Committee on Jean Julliard Prize 40 • Cellular Therapy Working Party 15 • ISBT Standing Committee of Vox Sanguinis 42 • Clinical Transfusion Working Party 16 • Report from Vox Sanguinis 43 • Donors and Donation Working Party 18 • Report from the ISBT Science Series 45 • Global Blood Safety Working Party 19 • Report from ISBT Foundation 47 • Granulocyte Immunobiology Working Party 21 • ISBT Award and Prizes 48 • Haemovigilance Working Party 22 • Immunohaematology Working Party 24 • Information Technology Working Party 25 Corporate Partners ISBT is pleased to acknowledge the following Corporate Partners during 2020-2021 2 2020-2021 Annual Report MISSION, VISION AND GOALS The International Society of Blood Transfusion (ISBT) is a scientific society that was founded in 1935. Since that time the ISBT has grown in to an international society where transfusion medicine professionals from across the globe come together and do the one thing they do best: share knowledge to improve the safety of blood transfusion worldwide.
    [Show full text]
  • Common Cooking Spice Shows Promise in Combating Diabetes and Obesity 21 June 2008
    Common cooking spice shows promise in combating diabetes and obesity 21 June 2008 Shown to reverse inflammation associated with The inflammation associated with obesity was obesity and improves blood sugar control shown several years ago by researchers in the Turmeric, an Asian spice found in many curries, Naomi Berrie Diabetes Center to be due in part to has a long history of use in reducing inflammation, the presence of immune cells called macrophages healing wounds and relieving pain, but can it in fat tissues throughout the body. These cells prevent diabetes? Since inflammation plays a big produce "cytokine" molecules that can cause role in many diseases and is believed to be inflammation in organs such as the heart, and islets involved in onset of both obesity and Type 2 of the pancreas, while also increasing insulin diabetes, Drew Tortoriello, M.D., an resistance in muscle and liver. Researchers endocrinologist and research scientist at the Naomi hypothesized that by suppressing the number and Berrie Diabetes Center at Columbia University activity of these cells, with turmeric or a drug with Medical Center, and his colleagues were curious similar actions, it may be possible to reduce some what effect the herb might have on diabetic mice. of the adverse consequences of obesity. Dr. Tortoriello, working with pediatric resident Curcumin administration was also associated with a Stuart Weisberg, M.D., Ph.D., and Rudolph Leibel, small but significant decline in body weight and fat M.D., fellow endocrinologist and the co-director of content, despite level or higher calorie the Naomi Berrie Diabetes Center, discovered that consumption, suggesting that curcumin beneficially turmeric-treated mice were less susceptible to influences body composition.
    [Show full text]
  • NIDDK September 2020 Meeting Minutes
    National Diabetes and Digestive and Kidney Diseases Advisory Council National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Department of Health and Human Services I. CALL TO ORDER Dr. Rodgers Dr. Griffin Rodgers, Director, NIDDK, called to order the 214th meeting of the National Diabetes and Digestive and Kidney Diseases Advisory Council at 10:30 a.m. on September 9, 2020, via Zoom videoconference. This meeting was conducted using a two-tiered webinar format. The panelist tier consisted of NIDDK's Advisory Council members and NIDDK staff members who presented during the meeting. The audience tier was available to members of the public and allowed them to view and listen to the meeting. A. ATTENDANCE – COUNCIL MEMBERS PRESENT Dr. David D’Alessio* Dr. Iain Drummond Dr. Richard Peek Dr. Penny Gordon-Larsen Dr. David Penson Dr. Lisa Guay-Woodford Dr. Jeffrey Pessin Dr. Barbara Kahn Ms. Ceciel Rooker Mr. Richard Knight Dr. Kathleen Sakamoto Dr. Rudolph Leibel + Dr. Ronald Sokol Mr. Thomas Nealon Dr. Gary Wu Dr. Mark Nelson Also Present: Dr. Griffin Rodgers, Director, NIDDK and Chair of the NIDDK Advisory Council Dr. Karl F. Malik, Executive Secretary, NIDDK Advisory Council Dr. Matthew Portnoy, Deputy Director, Division of Extramural Activities Dr. Gregory G. Germino, Deputy Director, NIDDK Dr. Stephen P. James, Director, Division of Digestive Diseases and Nutrition, NIDDK Dr. Robert A. Star, Director, Division of Kidney, Urologic, and Hematologic Diseases, NIDDK Dr. William Cefalu, Director, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK * Ex officio member + Ad hoc member B. NIDDK PANELISTS/SPEAKERS Dr.
    [Show full text]
  • Annual Directors Meeting Norc Eab Member Receives
    Grant #2P30DK072476 October 2012 ANNUAL DIRECTORS MEETING In This Issue: This year’s annual NORC director’s meeting is being held on October 2 - 3, 2012, at LSU - Pennington Biomedical Research Center in Baton Pg. 1 NORC Directors Meeting Rouge, LA. There are 12 NORCs around the United States who will be involved in this annual meeting. Each year a different NORC hosts EAB Member Receives the annual meeting; PBRC was honored as the host of this year’s Honorary Doctorate Degree event. Pg. 2 Training Update The meeting is comprised of the 12 center directors and their Pg. 3 Core Capabilities and executive administrators. This years annual meeting will include a Upgrades presentation from Dr. Greg Germino and Dr. Mary Evans from NIH. Next on the agenda is a discussion on recurring methods across the Pg. 6 2011 Pilot and Feasibility different centers including; imaging and energy expenditure focusing Updates on standard operating procedures, methodology, and quality control. Potential collaborative topics will be discussed, specifically one Pg. 8 New Pilot and Feasibility already initiated by UAB NORC (Emily Dhurandhar) known as the 2012 Awards “Breakfast Study”. NORC EAB MEMBER RECEIVES HONORARY DOCTORATE DEGREE Rudolph L. Leibel, M.D., received an Honoris Causa Doctorate, or honorary doctorate degree, for his internationally recognized diabetes research at the LSU Health Sciences Center (LSUHSC) commencement ceremonies on Thursday, May 17 in New Orleans. On Friday, May 18, he was honored at the Pennington Biomedical Research Center in Baton Rouge where he will also presented his work to the faculty and research staff. Dr.
    [Show full text]
  • Which Is the Preferred Blood Product for Fibrinogen Replacement in The
    SUPPLEMENT ARTICLE Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia— cryoprecipitate or fibrinogen concentrate? Melissa M. Cushing ,1 Thorsten Haas,2 Keyvan Karkouti,3,4 and Jeannie Callum5,6,7 PRO FIBRINOGEN CONCENTRATE: The importance of the targeted treatment of acquired FIBRINOGEN CONCENTRATE IS THE hypofibrinogenemia during hemorrhage with a PREFERRED BLOOD PRODUCT FOR concentrated fibrinogen product (either cryoprecipitate or FIBRINOGEN REPLACEMENT IN THE fibrinogen concentrate) cannot be underestimated. BLEEDING PATIENT WITH ACQUIRED Fibrinogen concentrate is a pathogen inactivated, pooled HYPOFIBRINOGENEMIA product that offers a highly purified single factor concentrate. Cryoprecipitate is a pooled product that hrough this section of our debate, we will attempt comes with a spectrum of other coagulation factors to convince you to abandon cryoprecipitate (if you which may further enhance (additional procoagulant have not already done so) for the management of effect) or even disturb (prothrombotic risk) hemostasis. hemorrhage in the presence of acquired hypo- Tfibrinogenemia (fibrinogen level less than 1.5-2.0 g/L). It is The pros and cons of each product are discussed. crucial for the safety of future generations of transfusion recip- ients that all blood products transfused are pathogen inactivated (where available, safe, and effective).1 Although there are numerous hurdles to the implementation of pathogen-inactivation technologies across all manufactured blood products
    [Show full text]
  • The Biology and Genetics of Obesity — a Century of Inquiries Chin Jou, Ph.D
    PERSPECTIVE Hepatitis C and the Criminal Justice System From the Departments of Medicine and and control of hepatitis B and C. Washing- 4. Varan AK, Mercer DW, Stein MS, Spaulding Epidemiology, Brown University (J.D.R.), and ton, DC: National Academies Press, 2010. AC. Hepatitis C seroprevalence among pris- the Center for Prisoner Health and Human 2. Rein DB, Wittenborn JS, Weinbaum CM, on inmates since 2001: still high but declin- Rights, Miriam Hospital (J.D.R., S.A.A.) — Sabin M, Smith BD, Lesesne SB. Forecasting ing. Public Health Rep 2014;129:187-95. both in Providence, RI; the University of the morbidity and mortality associated with 5. Rich JD, Chandler R, Williams BA, et al. California Riverside School of Medicine, prevalent cases of pre-cirrhotic chronic hep- How health care reform can transform the Riverside (S.A.A.); and the Division of Geri- atitis C in the United States. Dig Liver Dis health of criminal justice-involved individu- atrics, Department of Medicine, University 2011;43:66-72. als. Health Aff (Millwood) 2014;33:462-7. of California, San Francisco (B.A.W.). 3. Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration DOI: 10.1056/NEJMp1311941 1. Institute of Medicine. Hepatitis and liver in the United States. N Engl J Med 2011;364: Copyright © 2014 Massachusetts Medical Society. cancer: a national strategy for prevention 2081-3. HISTORY OF MEDICINE The Biology and Genetics of Obesity — A Century of Inquiries Chin Jou, Ph.D. Related article, p. 1909 he obese lack willpower; they Noorden delineated two types of case that some people were pre- Tovereat and underexercise — obesity: exogenous and endoge- disposed to obesity.
    [Show full text]
  • BCRP Brochure 2021 Class
    Boston Combined Residency Program This brochure describes the residency program as we assume it will -19 exist will in be JulyThe 2021, Pediatric by which time Residency authorities Training Program predict a vaccine to COVID of available. If thatBoston is not the Children’s case and the Hospital pandemic is still active, the program Harvard Medical School will be very similar but many of the and educational conferences and other group activities Bostonwill be virtual Medical instead Center Boston University School of Medicine of in-person, as they are today. August 2020 edi,on CLASS OF 2021.. BOSTON COMBINED RESIDENCY PROGRAM Boston Medical Center Boston Children’s Hospital CONTENTS History…………........................... 3 Rotation # descriptions.................. 47# Global health fellowships............ 84# BCRP…........................................ 3# Night call................................... 53# Global health grants………….… 84 # Boston Children’s Hospital........... 3# Longitudinal ambulatory.............. 54# Diversity and Inclusion................. 84# Boston Medical Center................. 8# Electives………………………….. 55# Salaries and benefits.................... 87# People……................................... 11 Individualized curriculum............ 56# Child care................................... 88# Program director biosketches...... 11# Academic development block.. 56# O$ce of fellowship training....... 88# Residency program leadership..... 12# Education.................................... 57# Cost of living..............................
    [Show full text]
  • 19 Respiratory Illness (CONCOR-1): Study Protocol for an International, Multicenter, Randomized, Open- Label Trial
    Convalescent plasma for adults with acute COVID- 19 respiratory illness (CONCOR-1): Study protocol for an international, multicenter, randomized, open- label trial Philippe Bégin Université de Montréal: Universite de Montreal Jeannie Callum University of Toronto Nancy Heddle McMaster University Richard Cook University of Waterloo Michelle P Zeller McMaster University Alan Tinmouth University of Ottawa Dean Fergusson Ottawa Hospital Research Institute Melissa M Cushing Weill Cornell Medicine Marshall J Glesby Weill Cornell Medical College: Weill Cornell Medicine Michaël Chassé Université de Montréal Dana V Devine Canadian Blood Services Nancy Robitaille Héma-Québec Renée Bazin Héma-Québec Nadine Shehata University of Toronto Andrés Finzi Université de Montréal Page 1/34 Allison McGeer University of Toronto Damon Scales University of Toronto Lisa Schwartz McMaster University Alexis F Turgeon Universit Laval Ryan Zarychanski University of Manitoba Nick Daneman University of Toronto Richard Carl n/a Luiz Amorim Hemorio Caroline Gabe McMaster University Martin Ellis Tel Aviv University Erin Jamula McMaster University Julie Carruthers McMaster University Joanne Duncan McMaster University Kayla Lucier McMaster University Chantal Armali Sunnybrook Health Sciences Centre Amie Kron Sunnybrook Health Sciences Centre Dimpy Modi Sunnybrook Health Sciences Centre Marie-Christine Auclair Centre de recherche du CHU Sainte-Justine Meda Avram Centre de recherche du CHU Sainte-Justine Donald M Arnold ( [email protected] ) Page 2/34 McMaster University https://orcid.org/0000-0003-0943-8853 Research Article Keywords: convalescent plasma, SARS-CoV-2, coronavirus, COVID-19 Posted Date: March 5th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-268937/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License.
    [Show full text]